Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 57Terminated 20Active not recruiting 20Recruiting 18Withdrawn 7Unknown 5Suspended 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Lung Neoplasms 1

Interventions

Specimen Handling 15Biopsy 9Cyclophosphamide 8Magnetic Resonance Spectroscopy 7venetoclax 5Etoposide 4Azacitidine 4fludarabine phosphate 3X-Rays 3Tacrolimus 3Paclitaxel 3Interleukin-2 3Carboplatin 3zanubrutinib 2prednylidene 2fludarabine 2durvalumab 2deltacortene 2aldesleukin 2Vincristine 2Rituximab 2Radiotherapy, Intensity-Modulated 2Protein Subunit Vaccines 2Prednisone 2Nivolumab 2Melphalan 2Injections 2Gemcitabine 2E 7107 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Suspended × durvalumab × Clear all
NCT06963346 2026-03-09

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Suspended
12 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT05403723 2026-02-19

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

University of Maryland, Baltimore

Phase 1 Suspended
50 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡